Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525575 | 0.79 | KMT2A (0.47) | MAPTPOLBTDP1BCL2L1BCL2 | |
| SCHEMBL1113832 | 0.78 | BCL2L1 (0.64) | MAPTPOLBTDP1BCL2L1BCL2 | |
| SCHEMBL2943101 | 0.78 | MAPT (0.55) | MAPTPOLBTDP1BCL2L1DOT1L | |
| SCHEMBL2948667 | 0.77 | BCL2L1 (0.72) | BCL2L1BCL2 | |
| SCHEMBL2949663 | 0.76 | BCL2L1 (0.69) | MAPTPOLBTDP1BCL2L1BCL2 | |
| SCHEMBL28072225 | 0.76 | BCL2L1 (0.61) | MAPTPOLBTDP1BCL2L1BCL2 | |
| SCHEMBL6991148 | 0.76 | BCL2L1 (0.57) | MAPTPOLBTDP1BCL2L1DOT1L | |
| SCHEMBL5741850 | 0.75 | BCL2L1 (0.68) | MAPTPOLBTDP1BCL2L1BCL2 | |
| SCHEMBL9487112 | 0.74 | MAPT (1.00) | MAPTPOLBTDP1DOT1LPKM | |
| SCHEMBL29699504 | 0.74 | MAPT (1.00) | MAPTPOLBTDP1DOT1LPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| CN-1906183-B | N-acylsulfonamide apoptosis promoters | ABBOTT LAB | 2012-06-20 | — | — | CN | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | MAPT 4851/4885POLB 1110/4885TDP1 1063/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | MAPT 4830/4885POLB 859/4885TDP1 1246/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | MAPT 4851/4885POLB 1110/4885TDP1 1063/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAPT 4100/4885POLB 242/4885TDP1 885/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | MAPT 4640/4885POLB 530/4885TDP1 1386/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MAPT 4100/4885POLB 242/4885TDP1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.